Personal essays and analysis on Ozempic, weight-loss drugs, and the culture they created. Published intermittently. Always cultural, never prescriptive. Subscribe to the monthly letter to get the next one in your inbox.
Not medical advice, a cultural conversation. Ozemback is not affiliated with any pharmaceutical company or healthcare provider.
The cultural shorthand started in late 2024. Patients report blunted cravings (for food, alcohol, shopping, gambling, even Instagram). The mechanism is real: GLP-1 receptors are densely expressed in reward circuits. Here is the honest cultural read on what is signal and what is anecdote.
Read the essay →Coverage follows the plan's drug list and the reason for the prescription. FDA-approved drugs are a different question from compounded or research-labeled products.
Read more → Analysis · Market / regulatoryIndia launched generics in March 2026 and Canada approved the first G7 generic in April. The US date sits in seven confidential settlements, not in the 2032 patent.
Read more → Analysis · Regulatory / explainerA 503A pharmacy needs a prescription; a 503B outsourcing facility needs its ingredient on a federal list that holds five substances and no peptides. What that means, with dates and sources.
Read more → Analysis · Regulatory / explainerNot testosterone-related, not Schedule III. Yet FDA approval law, the growth-hormone statute, WADA 2026 and the DoD list regulate them anyway, with dates and sources.
Read more → Analysis · Market / supply chainThe label comes from diagnostics law and exempts nothing. FDA letters, a GLP-1-only border list, and test purchases that found 7.7% to 14.4% purity, traced link by link.
Read more → Analysis · Market / dataSold as a fat-loss peptide, it is a small molecule whose entire evidence base is 11 days in 18 mice. The FDA named it in a January 2026 warning letter. The market grew anyway.
Read more → Analysis · Regulatory referenceOf the eleven peptides people search for most, one is an FDA-approved drug on the market today. Six are only recommended by an advisory committee, which is not a legal status. Three are neither.
Read more → Analysis · Media & businessAt $6 to $18 RPM, the ad revenue is a rounding error. The video is the cheapest patient acquisition channel ever built, and the clinics, memberships, 35% dispensary margins and $18,000 certifications behind it are the real business.
Read more → Analysis · Verification / regulatoryThe tesamorelin figures circulating online are mostly not invented, they are expired. A fact-check against the FDA labels for Egrifta, Egrifta SV and Egrifta WR, which the agency says are not substitutable.
Read more → Essay · NewFor a century the equation had two terms: diet and exercise. Then a generation woke up and the sentence had a third. An essay on what that third sentence does to a culture.
Read more →